Karim Fizazi | Scholar Profiles and Rankings

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
Correlation analyses of radiographic progression‐free survival with clinical and health‐related quality of life outcomes in metastatic castration‐resistant prostate cancer: Analysis of the phase 3 VISION trial (journal article) Morris, Michael J. \| de Bono, Johann \| Nagarajah, James \| Sartor, Oliver \| Wei, Xiao X. \| Nordquist, Luke T. \| Koshkin, Vadim S. \| Chi, Kim N. \| Krause, Bernd J. \| Herrmann, Ken \| ... \| Tagawa, Scott T. Cancer (2024). 10.1002/cncr.35438 Cited by (1) \| Cite \| Source
Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with177 Lu-PSMA-617 versus change of ARPI in PSMAfore. (journal article) De Bono, Johann S. \| Morris, Michael J. \| Sartor, Oliver \| Wei, Xiao X. \| Fizazi, Karim \| Herrmann, Ken \| Piulats, Josep M. \| Mahammedi, Hakim \| Logothetis, Christopher \| George, Daniel J. \| ... \| Chi, Kim N. Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 5008-5008 (2024). 10.1200/JCO.2024.42.16_suppl.5008 Cite \| Source
Darolutamide plus androgen-deprivation therapy in patients with high-risk biochemical recurrence of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP). (journal article) Chehrazi-Raffle, Alex \| Morgans, Alicia K. \| Gschwend, Jürgen E. \| Shore, Neal D. \| Ross, Ashley \| Feng, Felix Y \| Hope, Thomas A. \| Nordquist, Luke \| Niazi, Tamim \| Trandafir, Lucia \| ... \| Fizazi, Karim Journal of Clinical Oncology, volume 42, issue 16_suppl, pages TPS5122-TPS5122 (2024). 10.1200/JCO.2024.42.16_suppl.TPS5122 Cite \| Source
CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA: Phase 3 MK-5684-004 study. (journal article) Fizazi, Karim \| Vile, Donald Charles \| Chen, Zheng Hong \| Poehlein, Christian Heinrich \| Todoric, Jelena \| Gratzke, Christian Journal of Clinical Oncology, volume 42, issue 16_suppl, pages TPS5114-TPS5114 (2024). 10.1200/JCO.2024.42.16_suppl.TPS5114 Cite \| Source
A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC). (journal article) Heath, Elisabeth I. \| Sharp, Adam \| Borchiellini, Delphine \| De Bono, Johann S. \| Fizazi, Karim \| Gravis, Gwenaelle \| Lorente, David \| Mahammedi, Hakim \| Mellado-Gonzalez, Begoña \| Olmos, David \| ... \| Bernard-Tessier, Alice Journal of Clinical Oncology, volume 42, issue 16_suppl, pages TPS5109-TPS5109 (2024). 10.1200/JCO.2024.42.16_suppl.TPS5109 Cite \| Source
Post-progression survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide or placebo: Post hoc analysis of ARASENS. (journal article) Grimm, Marc-Oliver \| Smith, Matthew Raymond \| Hussain, Maha H. A. \| Saad, Fred \| Fizazi, Karim \| Littleton, Natasha \| Paracha, Noman \| Srinivasan, Shankar \| Verholen, Frank \| Tombal, Bertrand F. Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 5083-5083 (2024). 10.1200/JCO.2024.42.16_suppl.5083 Cite \| Source
ODM-209, a CYP 11A1 inhibitor in patients with mCRPC: Results from the STESIDES phase 1 study. (journal article) Bernard-Tessier, Alice \| Spanggaard, Iben \| Utriainen, Tapio \| Tanner, Minna \| Rohrberg, Kristoffer Staal \| Naoun, Natacha \| Ikonen, Tarja \| Pohjanjousi, Pasi \| Garratt, Chris \| Fizazi, Karim Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 5060-5060 (2024). 10.1200/JCO.2024.42.16_suppl.5060 Cite \| Source
Exploration of circulating tumor cell (CTC) conversion and CTC0 as prognostic biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metas (journal article) Yip, Steven \| Fizazi, Karim \| Laird, Douglas \| Matsubara, Nobuaki \| Azad, Arun \| Joung, Jae Young \| Fong, Peter C.C. \| Van Bruwaene, Siska \| Liu, Glenn \| Voog, Eric \| ... \| Agarwal, Neeraj Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 5023-5023 (2024). 10.1200/JCO.2024.42.16_suppl.5023 Cite \| Source
Discovery of a novel non-negative matrix factorization (NMF)-based homologous recombination deficiency (HRD) score and subsequent exploration in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first (journal article) Fizazi, Karim \| Roh, Whijae \| Azad, Arun \| Mu, Xinmeng Jasmine \| Matsubara, Nobuaki \| Yip, Steven \| Zschaebitz, Stefanie \| Piulats, Josep M. \| Liu, Glenn \| Jones, Robert J. \| ... \| Agarwal, Neeraj Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 5021-5021 (2024). 10.1200/JCO.2024.42.16_suppl.5021 Cite \| Source
Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate c (journal article) Azad, Arun \| Fizazi, Karim \| Laird, Douglas \| Matsubara, Nobuaki \| De Giorgi, Ugo \| ButtIgliero, Consuelo \| Karsh, Lawrence Ivan \| Joung, Jae Young \| Yip, Steven \| Zschaebitz, Stefanie \| ... \| Agarwal, Neeraj Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 5020-5020 (2024). 10.1200/JCO.2024.42.16_suppl.5020 Cite \| Source
Health-related quality of life and pain in a phase 3 study of [177 Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore). (journal article) Fizazi, Karim \| Morris, Michael J. \| Shore, Neal D. \| Chi, Kim N. \| Crosby, Michael \| De Bono, Johann S. \| Herrmann, Ken \| Roubaud, Guilhem \| Nagarajah, James \| Fleming, Mark T. \| ... \| Sartor, Oliver Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 5003-5003 (2024). 10.1200/JCO.2024.42.16_suppl.5003 Cite \| Source
Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes (journal article) Hussain, Maha \| Fizazi, Karim \| Shore, Neal D. \| Heidegger, Isabel \| Smith, Matthew R. \| Tombal, Bertrand \| Saad, Fred JAMA Oncology, volume 10, issue 6, pages 807- (2024). 10.1001/jamaoncol.2024.0591 Cite \| Source
Prevalence and Spectrum of AR Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer (journal article) Antonarakis, Emmanuel S. \| Zhang, Nicole \| Saha, Jayati \| Nevalaita, Liina \| Ikonen, Tarja \| Tsai, L. Jill \| Garratt, Chris \| Fizazi, Karim JCO Precision Oncology (2024). 10.1200/PO.23.00330 Cite \| Source
P2-04 EFFICACY OF [177 Lu]Lu-PSMA-617 VERSUS ARPI CHANGE IN TAXANE-NAIVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER BY PRE-RANDOMIZATION ARPI (PSMAFORE) (journal article) Shore, Neal \| Chi, Kim N. \| Morris, Michael J. \| Sartor, Oliver \| Fizazi, Karim \| Fléchon, Aude \| Študentová, Hana \| Kim, Hyun \| Kreisl, Teri N. \| Ghebremariam, Samson \| ... \| Wei, Xiao X. Journal of Urology, volume 211, issue 5S2 (2024). 10.1097/01.JU.0001015816.87470.c9.04 Cite \| Source
Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer (journal article) Grisay, Guillaume \| Lavaud, Pernelle \| Fizazi, Karim Current Oncology Reports, volume 26, issue 5, pages 488-495 (2024). 10.1007/s11912-024-01509-6 Cited by (1) \| Cite \| Source
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the (journal article) Saad, Fred \| Hussain, Maha H.A. \| Tombal, Bertrand \| Fizazi, Karim \| Sternberg, Cora N. \| Crawford, E. David \| Nordquist, Luke T. \| Bögemann, Martin \| Tutrone, Ronald \| Shore, Neal D. \| ... \| Smith, Matthew R. European Urology (2024). 10.1016/j.eururo.2024.03.036 Cited by (1) \| Cite \| Source
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer (journal article) Chi, Kim N. \| Armstrong, Andrew J. \| Krause, Bernd J. \| Herrmann, Ken \| Rahbar, Kambiz \| de Bono, Johann S. \| Adra, Nabil \| Garje, Rohan \| Michalski, Jeff M. \| Kempel, Mette M. \| ... \| Tagawa, Scott T. European Urology, volume 85, issue 4, pages 382-391 (2024). 10.1016/j.eururo.2023.12.004 Cited by (1) \| Cite \| Source
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial (journal article) Shore, Neal D \| Hussain, Maha \| Saad, Fred \| Fizazi, Karim \| Sternberg, Cora N \| Crawford, David \| Tombal, Bertrand \| Nordquist, Luke \| Cookson, Michael \| Verholen, Frank \| ... \| Smith, Matthew R The Oncologist, volume 29, issue 3, pages 235-243 (2024). 10.1093/oncolo/oyad254 Cited by (1) \| Cite \| Source
Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial (journal article) Tombal, B. \| Hussain, M. \| Saad, F. \| Fizazi, K. \| Shore, N. \| Kopyltsov, E. \| Bögemann, M. \| Mendez-Vidal, M.J. \| Littleton, N. \| Srinivasan, S. \| ... \| Smith, M.R. European Urology, volume 85 (2024). 10.1016/S0302-2838(24)01220-X Cite \| Source
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer (journal article) Xie, W. \| Ravi, P. \| Buyse, M. \| Halabi, S. \| Kantoff, P. \| Sartor, O. \| Soule, H. \| Clarke, N. \| Dignam, J. \| James, N. \| ... \| Sweeney, C.J. Annals of Oncology, volume 35, issue 3, pages 285-292 (2024). 10.1016/j.annonc.2023.11.017 Cited by (2) \| Cite \| Source